Dr. Ala is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
751 N Rutledge St
Springfield, IL 62702Phone+1 217-545-8417Fax+1 217-545-1903
Education & Training
- University of MinnesotaResidency, Neurology, 1986 - 1987
- University of MinnesotaResidency, Neurology, 1981 - 1985
- University of Minnesota Medical SchoolClass of 1981
Certifications & Licensure
- IL State Medical License 1999 - 2026
- MN State Medical License 1985 - 2000
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI) Start of enrollment: 2013 Mar 01
- A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology Start of enrollment: 2013 Jun 01
Publications & Presentations
PubMed
- Clinical Manifestations.Mark S Overby, Sean McGinity, Albert Botchway, Ronald F Zec, Thomas A Ala
Alzheimer's & Dementia. 2024-12-01 - Adapting Components of the Multimodal Minds in Motion Activity Program into General Practice.Greg Kyrouac, Susan Helm, Thomas Ala
Gerontology & Geriatric Medicine. 2022-12-20 - 1 citationsCognitive Component Structure of a Neuropsychological Battery Administered to Cognitively-Normal Adults in the SIU Longitudinal Cognitive Aging Study.Madison G Hollinshead, Albert Botchway, Kathleen E Schmidt, Gabriella L Weybright, Ronald F Zec
Gerontology & Geriatric Medicine. 2022-10-17
Press Mentions
- Safety and Efficacy of Edonerpic Maleate for Patients with Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical TrialJuly 8th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: